Apyx Medical CorporationAPYXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank67
3Y CAGR+25.0%
5Y CAGR-7.9%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+25.0%/yr
vs +2.2%/yr prior
5Y CAGR
-7.9%/yr
Recent acceleration
Acceleration
+22.8pp
Accelerating
Percentile
P67
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 30.83% |
| Q3 2025 | -170.69% |
| Q2 2025 | -97.89% |
| Q1 2025 | 76.21% |
| Q4 2024 | 30.72% |
| Q3 2024 | 0.54% |
| Q2 2024 | 27.57% |
| Q1 2024 | -1057.17% |
| Q4 2023 | -115.64% |
| Q3 2023 | 170.33% |
| Q2 2023 | -151.53% |
| Q1 2023 | 57.38% |
| Q4 2022 | 15.79% |
| Q3 2022 | 11.56% |
| Q2 2022 | -30.77% |
| Q1 2022 | -3965.25% |
| Q4 2021 | 96.87% |
| Q3 2021 | 25.02% |
| Q2 2021 | -124.38% |
| Q1 2021 | -59.72% |
| Q4 2020 | 46.48% |
| Q3 2020 | 48.73% |
| Q2 2020 | 31.71% |
| Q1 2020 | -107.90% |
| Q4 2019 | 29.39% |
| Q3 2019 | 14.70% |
| Q2 2019 | -17.95% |
| Q1 2019 | 72.32% |
| Q4 2018 | -1688.88% |
| Q3 2018 | -33.81% |
| Q2 2018 | 38.57% |
| Q1 2018 | -331.78% |
| Q4 2017 | 165.53% |
| Q3 2017 | 28.98% |
| Q2 2017 | 59.99% |
| Q1 2017 | -345.83% |
| Q4 2016 | -1100.00% |
| Q3 2016 | 59.40% |
| Q2 2016 | 94.19% |
| Q1 2016 | -173.03% |